神经生长因子联合奥拉西坦治疗高血压脑出血回顾性研究

发布时间：2018-05-10 20:23

本文选题：奥拉西坦 + 神经生长因子　；参考：《中国医院药学杂志》2017年01期

【摘要】：目的:回顾性分析联合应用神经生长因子和奥拉西坦以及单独应用奥拉西坦对高血压性脑出血患者的临床疗效。方法:分析某院收治的96例高血压性脑出血患者,按照治疗方法分为联合应用神经生长因子和奥拉西坦组、奥拉西坦组和常规治疗组。对各组患者行mRS评分,NIHSS评分以及GCS评分以及记录患者死亡情况并进行分析。结果:经过治疗后各组间在NIHSS评分上无明显差异,P=0.639;mRS评分也无显著差异,P=0.309。治疗前后比较,联合治疗组NIHSS评分显著降低,P=0.044 5,P0.05;mRS评分无统计学差异,P=0.052 4。其他组治疗前后无统计学差异。另外,生存分析显示在死亡率上各组间无统计学差异。结论:联合应用奥拉西坦及神经生长因子能够改善高血压脑出血患者的神经功能恢复,但是和单独应用奥拉西坦以及常规治疗相比并没有明显的优势。另外,三种治疗方法对于患者生存率没有明显的影响。
[Abstract]:Objective: to retrospectively analyze the clinical effects of combined use of nerve growth factor and oxiracetam and olaxetam alone in patients with hypertensive intracerebral hemorrhage. Methods: 96 patients with hypertensive intracerebral hemorrhage were divided into three groups: nerve growth factor and olaxetam group, olaxetam group and routine treatment group. MRS scores, GCS scores and death were recorded and analyzed. Results: after treatment, there was no significant difference in NIHSS score between the groups and there was no significant difference in P0. 639 mRS score. Compared with before and after treatment, the NIHSS score of the combined treatment group was significantly lower than that of the control group. There was no significant difference in the scores of P0. 044 5 and 0. 05 mRS in the combined treatment group (P 0. 052 4). There was no statistical difference between the other groups before and after treatment. In addition, survival analysis showed no significant difference in mortality among groups. Conclusion: combined use of olaxetam and nerve growth factor can improve the recovery of nerve function in patients with hypertensive intracerebral hemorrhage, but there is no obvious advantage over olaxetam alone and routine treatment. In addition, the three treatments had no significant effect on the survival rate.
【作者单位】：正定县人民医院神经外科;
【基金】：石家庄市科技计划,石科[2014]101号基金资助项目(编号:141462653)
【分类号】：R743.34;R544.1

【相似文献】